Racura Oncology (ASX: RAC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Racura Oncology Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Racura Oncology (ASX: RAC)
Latest News
Share Gainers
Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher
Share Fallers
Why Meteoric Resources, Race, Temple & Webster, and West African shares are falling today
Share Gainers
Why Bravura, Dateline, Orthocell, and Race Oncology shares are storming higher
Healthcare Shares
Cancer drug developer's shares race to three-year high, up 20% on new research results
Share Gainers
Why Deterra Royalties, DroneShield, Lindian, and Race Oncology shares are rising today
Healthcare Shares
Guess which ASX All Ords share is up 9% on 'important milestone'
Healthcare Shares
Why did this ASX All Ords healthcare share just rocket 28%?
Share Gainers
3 ASX biotech shares rocketing 10% to 26% on BIG news!
Healthcare Shares
ASX IPO watch: Aspiring healthcare stock has attracted former Macquarie CEO to invest
Healthcare Shares
2 ASX healthcare shares having a stellar run today
Share Gainers
Why Pinnacle, PWR, Race Oncology, and Vulcan shares are flying today
Earnings Results
Two up, one down: ASX healthcare stocks split after FY24 results
Frequently Asked Questions
-
No, Racura Oncology does not pay dividends at this time.
-
Sydney-headquartered Racura Oncology listed on the ASX on 13 July 2016.
RAC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Racura Oncology
Racura Oncology (ASX: RAC) is a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
Racura’s lead asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1.
Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications, with Phase 3 clinical programs in acute myeloid leukaemia (AML), Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.
Racura Oncology has collaborated with Astex, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle. Racura is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world.
